Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Digital peer support: a new weapon against cancer treatment anxiety?

NCT ID NCT07766226

Symptom relief Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 14, 2026 · Last updated Sep 03, 2026 · Updated 2 times

Summary

This trial tests whether a mobile app that encourages social sharing and peer interaction can reduce anxiety and depression in people with head and neck cancer undergoing radiotherapy. Half of the 120 participants will use the app for eight weeks, while the other half receives a printed booklet. The study measures changes in anxiety and depression scores, as well as quality of life and treatment adherence.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A mobile app with social sharing, peer interaction, psychoeducational resources, and reminders
What this could lead to
If effective, this app could offer a scalable, accessible way to reduce anxiety and depression in cancer patients undergoing radiotherapy, improving quality of life and treatment adherence.
What could go wrong
The trial is relatively small and open-label, so results may be influenced by expectations. The app's benefit over standard care is uncertain, and engagement may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18 - 75 years, male or female 2. Life expectancy ≥ 6 months 3. Histopathologically confirmed head and neck squamous cell carcinoma (including nasopharyngeal carcinoma) without distant metastasis 4. Planned to receive curative radiotherapy or postoperative adjuvant radiotherapy 5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 6. Adequate cognitive and reading ability to complete questionnaires 7. Ability to use a smartphone or tablet device 8. Fluent in Chinese (reading and speaking) 9. Willing and able to provide signed informed consent Exclusion Criteria: 1. Other malignancies (except treated basal cell skin cancer or cervical CIS) 2. Prior head and neck radiotherapy 3. History of psychiatric disorder or psychotropic medication use 4. Absolute contraindication to head and neck radiotherapy 5. Uncontrolled systemic disease (poorly controlled DM, NYHA III-IV HF, interstitial lung disease)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Head and neck squamous cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Head and neck squamous cell carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • West China Hospital, Sichuan University

    RECRUITING

    Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.